Aduro Biotech, Inc.
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
50.0%
6 terminated/withdrawn out of 12 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
150%
9 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Role: collaborator
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Role: collaborator
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Role: collaborator
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
Role: lead
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Role: lead
Safety of ADU-1604 in Adults With Metastatic Melanoma
Role: lead
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Role: lead
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
Role: lead
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Role: lead
Phase I Study of Safety and Immunogenicity of ADU-623
Role: collaborator
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Role: lead
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
Role: lead
All 12 trials loaded